Literature DB >> 8816827

Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice.

J Turki1, J N Lorenz, S A Green, E T Donnelly, M Jacinto, S B Liggett.   

Abstract

A threonine to isoleucine polymorphism at amino acid 164 in the fourth transmembrane spanning domain of the beta 2-adrenergic receptor (beta 2AR) is known to occur in the human population. The functional consequences of this polymorphism to catecholamine signaling in relevant cells or to end-organ responsiveness, however, are not known. To explore potential differences between the two receptors, site-directed mutagenesis was carried out to mimic the polymorphism. Transgenic FVB/N mice were then created overexpressing wild-type (wt) beta 2AR or the mutant Ile-164 receptor in a targeted manner in the heart using a murine alpha myosin heavy chain promoter. The functional properties of the two receptors were then assessed at the level of in vitro cardiac myocyte signaling and in vivo cardiac responses in intact animals. The expression levels of these receptors in the two lines chosen for study were approximately 1200 fmol/mg protein in cardiac membranes, which represents a approximately 45-fold increase in expression over endogenous beta AR. Myocyte membrane adenylyl cyclase activity in the basal state was significantly lower in the Ile-164 mice (19.5 +/- 2.7 pmol/min/mg) compared with wt beta 2AR mice (35.0 +/- 4.1 pmol/min/mg), as was the maximal isoproterenol-stimulated activity (49.8 +/- 7.8 versus 77.1 +/ 7.3 pmol/min/mg). In intact animals, resting heart rate (441 +/- 21 versus 534 +/- 17 bpm) and dP/dtmax (10,923 +/- 730 versus 15,308 +/- 471 mmHg/sec) were less in the Ile-164 mice as compared with wt beta 2AR mice. Similarly, the physiologic responses to infused isoproterenol were notably less in the mutant expressing mice. Indeed, these values, as well as other contractile parameters, were indistinguishable between Ile-164 mice and nontransgenic littermates. Taken together, these results demonstrate that the Ile-164 polymorphism is substantially dysfunctional in a relevant target tissue, as indicated by depressed receptor coupling to adenylyl cyclase in myocardial membranes and impaired receptor mediated cardiac function in vivo. Under normal homeostatic conditions or in circumstances where sympathetic responses are compromised due to diseased states, such as heart failure, this impairment may have important pathophysiologic consequences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816827      PMCID: PMC38411          DOI: 10.1073/pnas.93.19.10483

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor.

Authors:  B K Kobilka; R A Dixon; T Frielle; H G Dohlman; M A Bolanowski; I S Sigal; T L Yang-Feng; U Francke; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

3.  Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.

Authors:  M R Bristow; R E Hershberger; J D Port; W Minobe; R Rasmussen
Journal:  Mol Pharmacol       Date:  1989-03       Impact factor: 4.436

4.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.

Authors:  C D Strader; M R Candelore; W S Hill; I S Sigal; R A Dixon
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

5.  An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation.

Authors:  J W Black; P Leff; N P Shankley; J Wood
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

6.  Beta 1- and beta 2-adrenergic receptors display subtype-selective coupling to Gs.

Authors:  S A Green; B D Holt; S B Liggett
Journal:  Mol Pharmacol       Date:  1992-05       Impact factor: 4.436

7.  Desensitization of myocardial beta-adrenergic receptors during cardiopulmonary bypass. Evidence for early uncoupling and late downregulation.

Authors:  D A Schwinn; B J Leone; D R Spahn; L C Chesnut; S O Page; R L McRae; S B Liggett
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

8.  Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor.

Authors:  W J Koch; H A Rockman; P Samama; R A Hamilton; R A Bond; C A Milano; R J Lefkowitz
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

9.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects.

Authors:  E Reihsaus; M Innis; N MacIntyre; S B Liggett
Journal:  Am J Respir Cell Mol Biol       Date:  1993-03       Impact factor: 6.914

10.  Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy.

Authors:  O E Brodde; S Schüler; R Kretsch; M Brinkmann; H G Borst; R Hetzer; J C Reidemeister; H Warnecke; H R Zerkowski
Journal:  J Cardiovasc Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.105

View more
  32 in total

Review 1.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

2.  Transgenic Galphaq overexpression induces cardiac contractile failure in mice.

Authors:  D D D'Angelo; Y Sakata; J N Lorenz; G P Boivin; R A Walsh; S B Liggett; G W Dorn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 3.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

4.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

Review 5.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 6.  Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.

Authors:  Gerald W Dorn; Stephen B Liggett
Journal:  Mol Pharmacol       Date:  2009-06-02       Impact factor: 4.436

7.  Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance.

Authors:  R Winker; A Barth; E Valic; R Maier; W Osterode; A Pilger; H W Rüdiger
Journal:  Int Arch Occup Environ Health       Date:  2005-02-18       Impact factor: 3.015

8.  Ventricular function during exercise in mice and rats.

Authors:  Heidi L Lujan; Hussein Janbaih; Han-Zhong Feng; Jian-Ping Jin; Stephen E DiCarlo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-19       Impact factor: 3.619

Review 9.  Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure.

Authors:  Gerald W Dorn; Stephen B Liggett
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

10.  Bitransgenesis with beta(2)-adrenergic receptors or adenylyl cyclase fails to improve beta(1)-adrenergic receptor cardiomyopathy.

Authors:  Natalia Petrashevskaya; Brigitte R Gaume; Kathryn A Mihlbachler; Gerald W Dorn; Stephen B Liggett
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.